Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CIK plus S-1 chemotherapy in advanced gastric cancer
NCT01783951Phase 2Completed
- Sponsor
- Capital Medical University
- Start
- Feb 2013
- Primary completion
- Feb 2018
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dendritic cell vaccine + cytokine-induced killer cells in gastric cancer (GC) (2 arms), sponsored by Capital Medical University. Primary endpoint: Progression Free Survival at 4 years. Started Feb 2013; status: completed.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01783951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01783951.